Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...

Vantage Clinical Partners provides assessment, program development, and operational optimization services across key ...

In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Q4 2025 Management View CEO Paul LaViolette stated that Pulse Biosciences is “creating a pulsed field ablation platform to completely shift how physicians treat disease” by advancing nanosecond pulsed ...

While there are shared principles across development programs, Barr noted that the nuances within immunology, ophthalmology, or chronic care studies can determine whether a trial succeeds or fails.

Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...

The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

Core Economic Terms of $6.0 Million Financing Remain Unchanged Jupiter Neurosciences, Inc. (NASDAQ:JUNS)That alignment ...